JAZZ · Categories · Form 4
JAZZ - SEC Form 4 insider transactions
Jazz Pharmaceuticals plc (JAZZ) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.
Recent Form 4 for JAZZ
- EVP, Chief Commercial Officer Pearce Samantha covered exercise/tax liability with 780 units of Ordinary Shares, decreasing direct ownership by 2% to 47,131 units (SEC Form 4) to satisfy withholding tax4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- Director Winningham Rick E was granted 1,605 units of Ordinary Shares, increasing direct ownership by 17% to 11,172 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- Director Love Ted W was granted 1,605 units of Ordinary Shares, increasing direct ownership by 105% to 3,132 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- Director Hamill Laura was granted 1,605 units of Ordinary Shares, increasing direct ownership by 23% to 8,538 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- Director Kennedy Patrick was granted 1,605 units of Ordinary Shares, increasing direct ownership by 24% to 8,307 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- Director Smith Mark Douglas was granted 1,605 units of Ordinary Shares, increasing direct ownership by 17% to 11,285 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- Director Cook Jennifer E. was granted 1,605 units of Ordinary Shares, increasing direct ownership by 15% to 12,442 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- Director Mulligan Seamus was granted 1,605 units of Ordinary Shares, increasing direct ownership by 0.14% to 1,184,633 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- Director Mcsharry Heather Ann was granted 1,605 units of Ordinary Shares, increasing direct ownership by 9% to 20,054 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- Director Enright Patrick G was granted 1,605 units of Ordinary Shares, increasing direct ownership by 8% to 22,984 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- Director Riedel Norbert G was granted 1,605 units of Ordinary Shares, increasing direct ownership by 23% to 8,629 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- Director Cozadd Bruce C was granted 1,605 units of Ordinary Shares, increasing direct ownership by 0.44% to 362,287 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- Director Cozadd Bruce C sold $1,517,880 worth of Ordinary Shares (6,000 units at $252.98) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 360,682 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- Director Cozadd Bruce C sold $1,442,820 worth of Ordinary Shares (6,000 units at $240.47) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 366,682 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- EVP, Chief Commercial Officer Pearce Samantha covered exercise/tax liability with 2,527 units of Ordinary Shares, decreasing direct ownership by 5% to 47,911 units (SEC Form 4) (tax liability)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- President & CEO Gala Renee D covered exercise/tax liability with 4,835 units of Ordinary Shares, decreasing direct ownership by 3% to 147,361 units (SEC Form 4) (withholding tax)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- EVP, Global Head of R&D & CMO Iannone Robert covered exercise/tax liability with 3,764 units of Ordinary Shares, decreasing direct ownership by 4% to 85,107 units (SEC Form 4) (for tax liability)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- EVP & Chief Legal Officer Patil Neena M covered exercise/tax liability with 2,678 units of Ordinary Shares, decreasing direct ownership by 5% to 48,871 units (SEC Form 4) (withholding obligation)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- EVP & Chief Financial Officer Johnson Philip L covered exercise/tax liability with 3,343 units of Ordinary Shares, decreasing direct ownership by 6% to 56,431 units (SEC Form 4) (withholding tax)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- Director Smith Mark Douglas sold $266,746 worth of Ordinary Shares (1,157 units at $230.55) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 9,680 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- EVP & Chief Legal Officer Patil Neena M sold $278,196 worth of Ordinary Shares (1,200 units at $231.83) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 51,549 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- President & CEO Gala Renee D gifted 600 units of Ordinary Shares, decreasing direct ownership by 0.39% to 152,196 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- Director Cozadd Bruce C sold $1,410,720 worth of Ordinary Shares (6,000 units at $235.12) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 372,682 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- EVP & Chief Legal Officer Patil Neena M sold $282,468 worth of Ordinary Shares (1,192 units at $236.97) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 52,626 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- EVP, Chief Commercial Officer Pearce Samantha exercised 6,907 units of Ordinary Shares at a strike of $109.45 and sold $1,625,977 worth of Ordinary Shares (6,907 units at $235.41) (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- Director Mulligan Seamus exercised 3,415 units of Ordinary Shares at a strike of $138.08, increasing direct ownership by 0.29% to 1,183,028 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- Director Winningham Rick E exercised 3,415 units of Ordinary Shares at a strike of $138.08 and sold $662,143 worth of Ordinary Shares (2,741 units at $241.57), increasing direct ownership by 8% to 9,567 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- Director Mcsharry Heather Ann sold $482,000 worth of Ordinary Shares (2,000 units at $241.00), decreasing direct ownership by 10% to 18,449 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- Director Cozadd Bruce C sold $1,219,980 worth of Ordinary Shares (6,000 units at $203.33) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 378,682 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- SEC Form 4 filed by Cozadd Bruce C4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- Director Cozadd Bruce C covered exercise/tax liability with 15,114 units of Ordinary Shares, decreasing direct ownership by 4% to 390,682 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- EVP & Chief Financial Officer Johnson Philip L covered exercise/tax liability with 2,615 units of Ordinary Shares, decreasing direct ownership by 4% to 59,608 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- SVP, Technical Operations Henderson Mary Elizabeth covered exercise/tax liability with 1,394 units of Ordinary Shares, decreasing direct ownership by 5% to 27,334 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- EVP, Chief Commercial Officer Pearce Samantha covered exercise/tax liability with 2,503 units of Ordinary Shares, decreasing direct ownership by 5% to 50,272 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- EVP, Global Head of R&D & CMO Iannone Robert covered exercise/tax liability with 6,209 units of Ordinary Shares, decreasing direct ownership by 7% to 88,871 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- SVP, Chief Accounting Officer Carr Patricia covered exercise/tax liability with 1,436 units of Ordinary Shares and sold $235,444 worth of Ordinary Shares (1,287 units at $182.94), decreasing direct ownership by 29% to 6,512 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- President & CEO Gala Renee D covered exercise/tax liability with 7,065 units of Ordinary Shares, decreasing direct ownership by 4% to 152,630 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- EVP & Chief Legal Officer Patil Neena M covered exercise/tax liability with 5,000 units of Ordinary Shares, decreasing direct ownership by 9% to 53,818 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- Director Cozadd Bruce C sold $1,118,613 worth of Ordinary Shares (6,000 units at $186.44), decreasing direct ownership by 1% to 405,796 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- Director Riedel Norbert G exercised 3,415 units of Ordinary Shares at a strike of $138.08 and sold $655,680 worth of Ordinary Shares (3,415 units at $192.00) (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- EVP & Chief Financial Officer Johnson Philip L was granted 11,857 units of Ordinary Shares, increasing direct ownership by 24% to 62,223 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- EVP, Chief Commercial Officer Pearce Samantha was granted 9,782 units of Ordinary Shares, increasing direct ownership by 23% to 52,775 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- EVP, Global Head of R&D & CMO Iannone Robert was granted 14,822 units of Ordinary Shares, increasing direct ownership by 18% to 95,080 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- SVP, Chief Accounting Officer Carr Patricia was granted 2,223 units of Ordinary Shares and sold $456,466 worth of Ordinary Shares (2,370 units at $192.60), decreasing direct ownership by 2% to 9,235 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- President & CEO Gala Renee D was granted 44,465 units of Ordinary Shares, increasing direct ownership by 39% to 159,695 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- Director Love Ted W was granted 1,527 units of Ordinary Shares (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- EVP & Chief Legal Officer Patil Neena M exercised 51,000 units of Ordinary Shares at a strike of $127.23, sold $10,650,482 worth of Ordinary Shares (55,600 units at $191.56) and was granted 10,079 units of Ordinary Shares, increasing direct ownership by 10% to 58,818 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- SVP, Technical Operations Henderson Mary Elizabeth was granted 4,447 units of Ordinary Shares and sold $1,039,134 worth of Ordinary Shares (5,343 units at $194.49), decreasing direct ownership by 3% to 28,728 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- SVP, Technical Operations Henderson Mary Elizabeth was granted 10,116 units of Ordinary Shares, increasing direct ownership by 52% to 29,624 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- SVP, Chief Accounting Officer Carr Patricia was granted 2,370 units of Ordinary Shares, increasing direct ownership by 34% to 9,382 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- EVP & Chief Legal Officer Patil Neena M was granted 8,852 units of Ordinary Shares and returned $560,549 worth of Ordinary Shares to the company (3,275 units at $171.16), increasing direct ownership by 12% to 53,339 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- EVP, Chief Commercial Officer Pearce Samantha was granted 3,637 units of Ordinary Shares and covered exercise/tax liability with 1,599 units of Ordinary Shares, increasing direct ownership by 5% to 42,993 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- EVP, Global Head of R&D & CMO Iannone Robert was granted 11,699 units of Ordinary Shares and covered exercise/tax liability with 4,140 units of Ordinary Shares, increasing direct ownership by 10% to 80,258 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- President & CEO Gala Renee D was granted 12,741 units of Ordinary Shares and covered exercise/tax liability with 5,371 units of Ordinary Shares, increasing direct ownership by 7% to 115,230 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- Director Cozadd Bruce C was granted 35,917 units of Ordinary Shares and covered exercise/tax liability with 17,453 units of Ordinary Shares, increasing direct ownership by 5% to 411,796 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- Director Enright Patrick G disposed of 5,000 units of Ordinary Shares, decreasing direct ownership by 19% to 21,379 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- SVP, Technical Operations Henderson Mary Elizabeth sold $379,366 worth of Ordinary Shares (2,238 units at $169.51), decreasing direct ownership by 10% to 19,508 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- President & CEO Gala Renee D covered exercise/tax liability with 80 units of Ordinary Shares, decreasing direct ownership by 0.07% to 107,860 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- SVP, Chief Accounting Officer Carr Patricia sold $797,783 worth of Ordinary Shares (4,660 units at $171.20) and exercised 4,500 units of Ordinary Shares at a strike of $140.67, decreasing direct ownership by 2% to 7,012 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- Director O'Keefe Kenneth W covered exercise/tax liability with 603 units of Ordinary Shares, decreasing direct ownership by 2% to 25,811 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)